|
1
|
Two phase 3 trials of bapineuzumab in mild-to-moderate Alzheimer's disease.
|
N Engl J Med
|
2014
|
6.50
|
|
2
|
11C-PiB PET assessment of change in fibrillar amyloid-beta load in patients with Alzheimer's disease treated with bapineuzumab: a phase 2, double-blind, placebo-controlled, ascending-dose study.
|
Lancet Neurol
|
2010
|
5.03
|
|
3
|
Amyloid-related imaging abnormalities in patients with Alzheimer's disease treated with bapineuzumab: a retrospective analysis.
|
Lancet Neurol
|
2012
|
2.75
|
|
4
|
Effect of immunotherapy with bapineuzumab on cerebrospinal fluid biomarker levels in patients with mild to moderate Alzheimer disease.
|
Arch Neurol
|
2012
|
2.61
|
|
5
|
Targeting Beta amyloid: a clinical review of immunotherapeutic approaches in Alzheimer's disease.
|
Int J Alzheimers Dis
|
2012
|
0.93
|
|
6
|
Global issues in drug development for Alzheimer's disease.
|
Alzheimers Dement
|
2011
|
0.84
|